The goal of the Cancer Genetics and Epigenetics (CGE) Program is to better understand the fundamental mechanisms underlying genetic and epigenetic instability and its contribution to the initiation and progression of human tumors. In pursuit of this goal, the program organizes its research efforts into three areas of focus: 1) DNA damage and repair and genome instability;2) epigenetics and gene regulation;and 3) cancer genetics /genomics. The CGE Program consists of 29 core members from 13 academic departments and three schools across Emory University, including the School of Medicine, the School of Public Health and Emory College. CGE Program members currently have $15,110,592 in research grant funding (annual direct costs), of which $12,849,105 is peer-reviewed and $4,277,290 (34%) is NCI-funded. Program members have published 227 cancer-related publications in the cun-ent project period. Among these, 12% and 25% represent intra- and inter-programmafic and interactions, respectively. In the current project period, discovery efforts have led to the identification of key genes whose mutation or altered expression contribute to cancer initiation and progression. Basic discoveries in the area of cancer epigenetics have prompted early small molecule screening efforts to identify novel targeted agents. Program development and key recruitments have strengthened and enhanced intra-programmatic activities in the areas of human radiation carcinogenesis, DNA damage/repair, and cancer genomics. This has been leveraged into several new multi-investigator grants and has provided key translational avenues for the program through increased inter-programmatic activities and cross-cutting genomics initiatives. Successful genomic studies resulted in the molecular classification of tumors and the identification of genes, gene signatures, and clinical factors with prognostic value in prostate, breast, brain, and lung malignancies. The Cancer Genetics and Epigenetics Program facilitates scientific collaborations and cancer research discoveries and has positioned itself for continued development in the forthcoming project period.

Public Health Relevance

The CGE Program cultivates research collaborations that result in: 1) breakthroughs in understanding basic mechanisms that regulate normal and cancer cells;and 2) translation of basic findings into novel strategies for the prevention, detection, prognosis, and treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA138292-04
Application #
8512116
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-08-01
Project End
2017-03-31
Budget Start
2012-08-01
Budget End
2013-03-31
Support Year
4
Fiscal Year
2012
Total Cost
$30,220
Indirect Cost
$11,032
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Patel, Kirtesh R; Chowdhary, Mudit; Switchenko, Jeffrey M et al. (2016) BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res 26:387-94
Berg, Carla J; Stratton, Erin; Esiashvili, Natia et al. (2016) Young Adult Cancer Survivors' Experience with Cancer Treatment and Follow-Up Care and Perceptions of Barriers to Engaging in Recommended Care. J Cancer Educ 31:430-42
Yoshida, Michihiro; He, Peijian; Yun, C Chris (2016) Transgenic Expression of Human Lysophosphatidic Acid Receptor LPA2 in Mouse Intestinal Epithelial Cells Induces Intestinal Dysplasia. PLoS One 11:e0154527
Horton, John R; Liu, Xu; Gale, Molly et al. (2016) Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds. Cell Chem Biol 23:769-81
Bonner, Michael Y; Karlsson, Isabella; Rodolfo, Monica et al. (2016) Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. Oncotarget 7:12857-68
Bajpai, R; Matulis, S M; Wei, C et al. (2016) Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene 35:3955-64
Xiao, Canhua; Miller, Andrew H; Felger, Jennifer et al. (2016) A prospective study of quality of life in breast cancer patients undergoing radiation therapy. Adv Radiat Oncol 1:10-16
Owonikoko, Taofeek K; Zhang, Guojing; Kim, Hyun S et al. (2016) Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. J Transl Med 14:111
Oliver, Daniel E; Patel, Kirtesh R; Switchenko, Jeffrey et al. (2016) Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma. Melanoma Res 26:35-41
Liu, Min; Wang, Hongyan; Lee, Solah et al. (2016) DNA repair pathway choice at various conditions immediately post irradiation. Int J Radiat Biol 92:819-822

Showing the most recent 10 out of 210 publications